Datopotamab Deruxtecan in Advanced/Metastatic HER2- Breast Cancer: Results From the Phase 1 TROPION-Pantumor01 Study
Last Updated: Thursday, February 24, 2022
Datopotamab deruxtecan, an antibody-drug conjugate directed against trophoblast cell surface antigen-2 (Trop-2), is showing promise as a treatment for relapsed or refractory advanced triple-negative breast cancer, according to early findings from the phase I TROPION-PanTumor01 trial presented during the 2021 San Antonio Breast Cancer Symposium by Ian E. Krop, MD, PhD.
Advertisement
News & Literature Highlights